Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial

Abstract

Adalimumab was safe and effective in 68% of refractory uveitis patients 10 weeks after study enrolment, and maintained in 39% after 1 year. Ongoing study is required to determine the place of adalimumab and other TNF blockers in the treatment of uveitis.